Quercetin Induces Growth Arrest Through Activation of FOXO1 Transcription Factor in EGFR-overexpressing Oral Cancer Cells
Overview
Nutritional Sciences
Affiliations
The squamous cell carcinomas of the head and neck (SCCHNs) with aberrant epidermal growth factor receptor (EGFR) signaling are often associated with poor prognosis and low survival. Therefore, efficient inhibition of the EGFR signaling could intervene with the development of malignancy. Quercetin appears to be antitumorigenesis, but the underlying mechanism remains unclear in oral cancer. Fork-head box O (FOXO) transcription factors, Akt downstream effectors, are important regulators of cell growth. Here, we hypothesized that FOXO1 might be crucial in quercetin-induced growth inhibition in EGFR-overexpressing oral cancer. Quercetin treatment suppressed cell growth by inducing G2 arrest and apoptosis in EGFR-overexpressing HSC-3 and TW206 oral cancer cells. Quercetin inhibited EGFR/Akt activation with a concomitant induction of FOXO1 activation. FOXO1 knockdown attenuated quercetin-induced p21 and FasL expression and subsequent G2 arrest and apoptosis, respectively. Likewise, quercetin suppressed tumor growth in HSC-3 xenograft mice. Taken together, our data indicate that quercetin is an effective anticancer agent and that FOXO1 is crucial in quercetin-induced growth suppression in EGFR-overexpressing oral cancer.
Saadh M, Ahmed H, Chandra M, Al-Hussainy A, Hamid J, Mishra A Cancer Cell Int. 2025; 25(1):66.
PMID: 39994659 PMC: 11854426. DOI: 10.1186/s12935-025-03694-1.
Kim M, Lee J, Lee J J Lipid Atheroscler. 2024; 13(3):306-327.
PMID: 39355406 PMC: 11439752. DOI: 10.12997/jla.2024.13.3.306.
Chen J, Zhang X Curr Pharm Des. 2024; 31(5):391-412.
PMID: 39289945 DOI: 10.2174/0113816128328547240827045955.
An extensive analysis of the prognostic and immune role of FOXO1 in various types of cancer.
Li J, Wang C, Xu X, Chen J, Guo H Braz J Med Biol Res. 2024; 57:e13378.
PMID: 38716982 PMC: 11085032. DOI: 10.1590/1414-431X2024e13378.
Son H, Kim D Asian Pac J Cancer Prev. 2023; 24(1):283-289.
PMID: 36708578 PMC: 10152863. DOI: 10.31557/APJCP.2023.24.1.283.